Before I get rolling, I should I’ve got a few updates and thoughts for you on some stocks I own and sometimes write about, but first we’ve got a quick teaser solution to share with you — this one’s sort of a biotech stock (more of a diagnostics/device) stock, and it’s being teased by Tom Bulford, a UK newsletter guy who we write about from time to time.

The newsletter Bulford is pitching is one I haven’t noticed before, it’s called Breakthrough Biotech Alert and I suspect it was probably launched within the last couple years to take advantage of the wild bull market in biotech stocks — they’ve got it “on sale” for 997 Pounds right now, renewing at 1,497 Pounds per year (that’s about $2,300, for those of us on this side of the pond), and he’s pitching a few cancer-fighting ideas that he’ll give you if you subscribe… but most of the ad is about just one tiny stock that trades on the AIM in London and (very little) on the pink sheets in the US.

So what is it? Well, first let me give you a little taste of the ad:

“This is not a cure for cancer, but…

“This 3-stage ‘genetic filter’ can intercept cancer cells and destroy them before they become dangerous….

“Perhaps no-one will ever be able to say ‘we’ve beaten Cancer’ totally. That day may never come. But for these companies to make a potentially colossal climb in price – we don’t need a cure.

“That’s not what this is about.

“This is about being as close as we have ever been to making it a non-fatal disease.”

You can see the entire ad here if you like, I won’t force you to sit through too much of the spiel as I ID the stock, but the pitch is basically for “targeted” medicines and diagnostics — the ability to test individual patients and use drugs and treatments that are most likely to be effective against their particular cancer. You’ve probably seen a lot of this before, and we are continuing to see more and more drugs that are associated with some kind of testing — identifying before treatment which folks are most likely to benefit from the drug, and which folks shouldn’t take it at all.

Here’s a quick summary of Bulford’s basic description of that from ...